One institutional experience with imatinib mesylate in the treatment of gastrointestinal stromal tumors

被引：0
|
作者：
Tamas, Karin R.
Papai, Zsuzsa
Vegh, Eva A.
Petranyi, Agota E.
Szucs, Zoltan
Rohanszky, Magda
Aranyi, Zsuzsa
Bodoky, Gyorgy
机构：
[1] St Laslo Hosp, Budapest, Hungary
[2] Natl Med Ctr, Budapest, Hungary
来源：
ANNALS OF ONCOLOGY | 2006年 / 17卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：164 / 164
页数：1
相关论文
共 50 条
  • [31] Pathologic, radiologic and PET scan response of gastrointestinal stromal tumors after neoadjuvant treatment with imatinib mesylate
    Goh, B. K. P.
    Chow, P. K. H.
    Chuah, K. L.
    Yap, W. M.
    Wong, W. K.
    EJSO, 2006, 32 (09): : 961 - 963
  • [32] Efficacy of imatinib mesylate in from gastrointestinal stromal
    Fiorentini, G
    Bernardeschi, P
    De Simone, M
    Rossi, S
    Dentico, P
    Biancalani, M
    Scuderi, S
    Vaira, M
    Palomba, A
    JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 2003, 22 (04): : 13 - 16
  • [33] Polyclonal evolution of multiple secondary KIT mutations in gastrointestinal stromal tumors under treatment with imatinib mesylate
    Wardelmann, E
    Merkelbach-Bruse, S
    Pauls, K
    Thomas, N
    Schildhaus, HU
    Heinicke, T
    Speidel, N
    Pietsch, T
    Buettner, R
    Pink, D
    Reichardt, P
    Hohenberger, P
    CLINICAL CANCER RESEARCH, 2006, 12 (06) : 1743 - 1749
  • [34] Imatinib Mesylate for Patients With Unresectable or Recurrent Gastrointestinal Stromal Tumors: 10-Year Experience From Vietnam
    Kien Do Hung
    Quang Le Van
    Gia Nguyen Hoang
    Phuong Nguyen Thi Bich
    CANCER CONTROL, 2019, 26 (01) : 1 - 7
  • [35] Imatinib Mesylate for Patients with Recurrent or Metastatic Gastrointestinal Stromal Tumors Expressing KIT: A Decade Experience from Taiwan
    Yeh, Chun-Nan
    Chen, Yen-Yang
    Tseng, Jeng-Hwei
    Chen, Jen-Shi
    Chen, Tsung-Wen
    Tsai, Chun-Yi
    Cheng, Chi-Tung
    Jan, Yi-Yin
    Chen, Miin-Fu
    TRANSLATIONAL ONCOLOGY, 2011, 4 (06): : 328 - 335
  • [36] Cost Effectiveness of Imatinib Mesylate in the Treatment of Advanced Gastrointestinal Stromal Tumours
    Daniel M. Huse
    Margaret von Mehren
    Gregory Lenhart
    Heikki Joensuu
    Charles Blanke
    Weiwei Feng
    Stan Finkelstein
    George Demetri
    Clinical Drug Investigation, 2007, 27 : 85 - 93
  • [37] Imatinib mesylate neoadjuvant treatment for rectal malignant gastrointestinal stromal tumor
    Hou, Ying-Yong
    Zhou, Yang
    Lu, Shao-Hua
    Qi, Wei-Dong
    Xu, Cheng
    Hou, Jun
    Tan, Yun-Shan
    WORLD JOURNAL OF GASTROENTEROLOGY, 2009, 15 (15) : 1910 - 1913
  • [38] Imatinib mesylate neoadjuvant treatment for rectal malignant gastrointestinal stromal tumor
    Ying-Yong Hou
    World Journal of Gastroenterology, 2009, 15 (15) : 1910 - 1913
  • [39] Cost effectiveness of imatinib mesylate in the treatment of advanced gastrointestinal stromal tumours
    Huse, Daniel M.
    von Mehren, Margaret
    Lenhart, Gregory
    Joensuu, Heikki
    Blanke, Charles
    Feng, Weiwei
    Finkelstein, Stan
    Demetri, George
    CLINICAL DRUG INVESTIGATION, 2007, 27 (02) : 85 - 93
  • [40] Update on imatinib for gastrointestinal stromal tumors: duration of treatment
    Linch, Mark
    Claus, Jeroen
    Benson, Charlotte
    ONCOTARGETS AND THERAPY, 2013, 6 : 1011 - 1023
12345